Last reviewed · How we verify
Abdul El-Rabbany — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cefazolin Injection | Cefazolin Injection | marketed | ||||
| Cefazolin 2 GM Injection | Cefazolin 2 GM Injection | marketed | First-generation cephalosporin | Penicillin-binding proteins (PBPs) | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Stony Brook University · 1 shared drug class
- University of Florida · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Abdul El-Rabbany:
- Abdul El-Rabbany pipeline updates — RSS
- Abdul El-Rabbany pipeline updates — Atom
- Abdul El-Rabbany pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Abdul El-Rabbany — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abdul-el-rabbany. Accessed 2026-06-10.